SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2840
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease ; volume:16 ; number:1 ; day:16 ; month:5 ; year:2017 ; pages:1-11 ; date:12.2017
Cardiovascular diabetology ; 16, Heft 1 (16.5.2017), 1-11, 12.2017
- Schlagwort
-
Harnwege
Lymphsystem
Sekretion
Drüse
Endokrinium
Blutbildendes Gewebe
- Urheber
-
Zou, Honghong
- Beteiligte Personen und Organisationen
-
Zhou, Baoqin
Xu, Gaosi
SpringerLink (Online service)
- DOI
-
10.1186/s12933-017-0547-1
- URN
-
urn:nbn:de:1111-2017060915751
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zou, Honghong
- Zhou, Baoqin
- Xu, Gaosi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease
Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis
The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes
Overexpression of SGLT2 in the kidney of a P. gingivalis LPS-induced diabetic nephropathy mouse model
Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice?
Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality
Nonproteinuric diabetic kidney disease
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
SGLT2 inhibition mitigates transition from acute kidney injury to chronic kidney disease by suppressing ferroptosis
Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease
Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis
The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes
Overexpression of SGLT2 in the kidney of a P. gingivalis LPS-induced diabetic nephropathy mouse model
Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice?
Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality
Nonproteinuric diabetic kidney disease
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
SGLT2 inhibition mitigates transition from acute kidney injury to chronic kidney disease by suppressing ferroptosis
Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease
Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis
The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes
Overexpression of SGLT2 in the kidney of a P. gingivalis LPS-induced diabetic nephropathy mouse model
Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice?
Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality
Nonproteinuric diabetic kidney disease
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?